Free Trial Information
BioCentury | Sep 19, 2016
Clinical News

Omega-3 phospholipids: Bridging study data

...on safety and efficacy from the scientific literature or from previously approved products. In 2008, Neptune Technologies...
Read More
BioCentury | Nov 3, 2014
Clinical News

Omega-3 phospholipids: Phase II data

...finalize its next steps for CaPre, including a Phase III trial, with FDA. In 2008, Neptune Technologies...
Read More
BioCentury | May 26, 2014
Company News

Neptune Technologies management update

Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT; TSX:NTB), Laval, Quebec Business: Nutraceuticals, Cardiovascular, Neurology Transitioned: Andre Godin, CFO of Neptune, to interim president and CEO of Neptune and Neptune's Acasti Pharma Inc. and NeuroBioPharm subsidiaries; Godin...
Read More
BioCentury | May 5, 2014
Company News

Neptune Technologies & Bioressources Inc management update

Neptune Technologies & Bioressources Inc . (NASDAQ:NEPT; TSX:NTB), Laval, Quebec Business: Nutraceuticals, Cardiovascular, Neurology Resigned: Henri Harland as president and CEO of Neptune and Neptune's NeuroBioPharm Inc. and Acasti Pharma Inc. subsidiaries, while remaining a director...
Read More
BioCentury | May 5, 2014
Company News

Acasti, Enzymotec, Neptune Technologies nutraceuticals news

...treat hypertriglyceridemia. Acasti Pharma Inc. (TSX-V:APO; NASDAQ:ACST), Laval, Quebec Enzymotec Ltd. (NASDAQ:ENZY), Migdal HaEmeq, Israel Neptune Technologies...
Read More
BioCentury | Apr 14, 2014
Financial News

Neptune Technologies completes private placement

Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT; TSX:NTB), Laval, Quebec Business: Nutraceuticals, Cardiovascular, Neurology Date completed: 4/4/14 Type: Private placement Raised: C$2.5 million ($2.3 million) Shares: 907,000 Price: C$2.76 Shares after offering: 74.2 million Placement...
Read More
BioCentury | Apr 7, 2014
Finance

2Q14 Financial Markets Preview: Minor adjustment

...3/4/14 $55.2 $241.2 $215.6 -11% Compugen Ltd. (NASDAQ:CGEN; Tel Aviv:CGEN) 2/28/14 $72.5 $507.2 $507.7 0% Neptune Technologies...
Read More
BioCentury | Mar 10, 2014
Financial News

Neptune Technologies completes follow-on

Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT; TSX:NTB), Laval, Quebec Business: Nutraceuticals, Cardiovascular, Neurology Date completed: 2/28/14 Type: Follow-on Raised: $28.8 million Shares: 11.5 million Price: $2.50 Shares after offering: 73.3 million Underwriters: Roth Capital...
Read More
BioCentury | Oct 21, 2013
Financial News

Neptune Technologies financial update

...Quebec provincial government. The loan bears interest at 7% and is due in four years. Neptune Technologies...
Read More
BioCentury | Sep 2, 2013
Clinical News

CaPre omega-3 phospholipids: Phase II data

...to include the 4 g dose following a recommendation from FDA (see BioCentury, Jan. 7). Neptune Technologies...
Read More
Items per page:
1 - 10 of 29
BioCentury | Sep 19, 2016
Clinical News

Omega-3 phospholipids: Bridging study data

...on safety and efficacy from the scientific literature or from previously approved products. In 2008, Neptune Technologies...
Read More
BioCentury | Nov 3, 2014
Clinical News

Omega-3 phospholipids: Phase II data

...finalize its next steps for CaPre, including a Phase III trial, with FDA. In 2008, Neptune Technologies...
Read More
BioCentury | May 26, 2014
Company News

Neptune Technologies management update

Neptune Technologies & Bioressources Inc. (NASDAQ:NEPT; TSX:NTB), Laval, Quebec Business: Nutraceuticals, Cardiovascular, Neurology Transitioned: Andre Godin, CFO of Neptune, to interim president and CEO of Neptune and Neptune's Acasti Pharma Inc. and NeuroBioPharm subsidiaries; Godin...
Read More
BioCentury | May 5, 2014
Company News

Neptune Technologies & Bioressources Inc management update

Neptune Technologies & Bioressources Inc . (NASDAQ:NEPT; TSX:NTB), Laval, Quebec Business: Nutraceuticals, Cardiovascular, Neurology Resigned: Henri Harland as president and CEO of Neptune and Neptune's NeuroBioPharm Inc. and Acasti Pharma Inc. subsidiaries, while remaining a director...
Read More
BioCentury | May 5, 2014
Company News

Acasti, Enzymotec, Neptune Technologies nutraceuticals news

...treat hypertriglyceridemia. Acasti Pharma Inc. (TSX-V:APO; NASDAQ:ACST), Laval, Quebec Enzymotec Ltd. (NASDAQ:ENZY), Migdal HaEmeq, Israel Neptune Technologies...
Read More
BioCentury | Apr 14, 2014
Financial News

Neptune Technologies completes private placement

Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT; TSX:NTB), Laval, Quebec Business: Nutraceuticals, Cardiovascular, Neurology Date completed: 4/4/14 Type: Private placement Raised: C$2.5 million ($2.3 million) Shares: 907,000 Price: C$2.76 Shares after offering: 74.2 million Placement...
Read More
BioCentury | Apr 7, 2014
Finance

2Q14 Financial Markets Preview: Minor adjustment

...3/4/14 $55.2 $241.2 $215.6 -11% Compugen Ltd. (NASDAQ:CGEN; Tel Aviv:CGEN) 2/28/14 $72.5 $507.2 $507.7 0% Neptune Technologies...
Read More
BioCentury | Mar 10, 2014
Financial News

Neptune Technologies completes follow-on

Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT; TSX:NTB), Laval, Quebec Business: Nutraceuticals, Cardiovascular, Neurology Date completed: 2/28/14 Type: Follow-on Raised: $28.8 million Shares: 11.5 million Price: $2.50 Shares after offering: 73.3 million Underwriters: Roth Capital...
Read More
BioCentury | Oct 21, 2013
Financial News

Neptune Technologies financial update

...Quebec provincial government. The loan bears interest at 7% and is due in four years. Neptune Technologies...
Read More
BioCentury | Sep 2, 2013
Clinical News

CaPre omega-3 phospholipids: Phase II data

...to include the 4 g dose following a recommendation from FDA (see BioCentury, Jan. 7). Neptune Technologies...
Read More
Items per page:
1 - 10 of 29